Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report

Figure 1 Computed tomography scans of the lungs were obtained before and after treatment with cadonilimab. A: Computed tomography (CT) image of the chest on July 8, 2022, after grade 4 myelosuppression induced by chemotherapy; B: CT image of the chest on August 27, 2022, after three doses of cadonilimab; C: CT image of the chest on October 28, 2022, after treatment with cadonilimab; D: CT image of the chest on January 18, 2023, after treatment with cadonilimab; E: CT image of the chest on April 27, 2023, indicating complete remission (CR); F: CT image of the chest on July 24, 2023, showing that the patient achieved sustained CR.

Figure 2 The arterial phase of contrast-enhanced computed tomography of the liver was conducted before and after treatment with cadonilimab. A: Enhanced computed tomography (CT) image of the liver on July 8, 2022, after grade 4 myelosuppression was induced by chemotherapy; B: Enhanced CT image of the liver on August 27, 2022, after three doses of cadonilimab; C: Enhanced CT image of the liver on October 28, 2022, after treatment with cadonilimab; D: Enhanced CT image of the liver on January 18, 2023, after treatment with cadonilimab; E: Enhanced CT image of the liver on April 27, 2023, showing that the patient achieved complete remission (CR); F: Enhanced CT image of the liver on July 24, 2023, showing that the patient achieved sustained CR.

Figure 3 Critical diagnosis and treatment of the patient.